Novel presentations of periodic fever syndromes: Discrepancies between genetic and clinical diagnoses.
Journal
European journal of rheumatology
ISSN: 2147-9720
Titre abrégé: Eur J Rheumatol
Pays: Turkey
ID NLM: 101656068
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
19
02
2018
accepted:
12
08
2018
pubmed:
9
11
2018
medline:
9
11
2018
entrez:
9
11
2018
Statut:
ppublish
Résumé
The Periodic fever syndromes (PFS) are a group of disorders of the innate immune system. We investigated patients diagnosed with PFS at the Dartmouth Hitchcock Pediatric Rheumatology Clinic. Case acquisition was performed by reviewing ICD 9/10 coded records for familial Mediterranean fever (ICD 9 277.31), laboratory test records for PFS genetic screening, and clinic records between 1/1/2011 and 12/31/2017. Twenty-seven cases had clinical evaluations including PFS genetic screening. Clinical diagnoses included familial Mediterranean fever (FMF) (10 cases), Muckle-Wells (2 cases), tumor necrosis factor receptor associated periodic syndrome (TRAPS) (4 cases), hyper IgD syndrome (HIDS) (1 case), Crohn's Disease (1 case), systemic onset juvenile idiopathic arthritis (SoJIA) (1 case), fever of unknown origin (FUO) (1 case), periodic fever adenitis pharyngitis aphthous ulcer (PFAPA) (6 cases), and cold-induced urticaria (1 case). Fifteen cases were associated with a genetic cause. Seven of the 10 FMF cases were confirmed genetically and were either heterozygous or compound heterozygotes. Both cases of Muckle-Wells had either a compound heterozygote for CIAS 1 or a NOD gene mutation. Both TRAPS cases presented atypically with patients developing systemic lupus erythematosus (SLE) or being asymptomatic. Two patients had novel syndromes. One FMF patient had a TRNT1 gene mutation who responded to intravenous immunoglobulin (IVIg) and colchicine after failing multiple treatments. The other had SoJIA with a LPIN 2 gene mutation but responded to colchicine. Only one of the 15 genetically proven cases had classical presentation and genetics (HIDS secondary to a mevalonate kinase (MVK) gene mutation). PFS screening was helpful in over half of the cases to develop therapeutic treatment plans. Given the atypical clinical presentations seen with genetically determined PFS, extensive genetic testing is indicated for all patients presenting with a PFS, excluding classical PFAPA syndrome.
Identifiants
pubmed: 30407166
pii: eurjrheum.2018.18023
doi: 10.5152/eurjrheum.2018.18023
pmc: PMC6459325
doi:
Types de publication
Journal Article
Langues
eng
Pagination
12-18Références
Nat Genet. 1999 Jun;22(2):175-7
pubmed: 10369261
Am J Hum Genet. 1999 Oct;65(4):1054-9
pubmed: 10486324
Hum Mutat. 2000 Apr;15(4):385-6
pubmed: 10737995
Eur J Hum Genet. 2002 Feb;10(2):145-9
pubmed: 11938447
Am J Hum Genet. 2002 Jun;70(6):1498-506
pubmed: 11992256
Ann Rheum Dis. 2005 May;64(5):750-2
pubmed: 15458961
J Med Genet. 2005 Jul;42(7):551-7
pubmed: 15994876
Ann Rheum Dis. 2006 May;65(5):564-72
pubmed: 16219707
Rheumatol Int. 2006 Apr;26(6):489-96
pubmed: 16283319
Am J Hum Genet. 2008 Aug;83(2):243-53
pubmed: 18674748
Gut. 2009 Mar;58(3):388-95
pubmed: 18824555
Nephrol Dial Transplant. 2010 Aug;25(8):2520-3
pubmed: 19934083
Autoimmun Rev. 2012 Nov;12(1):38-43
pubmed: 22884554
Ann Rheum Dis. 2013 Mar;72(3):410-3
pubmed: 23087183
Blood. 2013 Jul 4;122(1):112-23
pubmed: 23553769
Asian Pac J Allergy Immunol. 2013 Dec;31(4):325-9
pubmed: 24383976
Neurologia. 2015 Jun;30(5):315-7
pubmed: 24485591
Nat Immunol. 2014 Aug;15(8):738-48
pubmed: 24952504
Nat Immunol. 2014 Aug;15(8):727-37
pubmed: 24952505
BMC Res Notes. 2014 Sep 27;7:678
pubmed: 25261084
J Allergy Clin Immunol. 2016 Jul;138(1):3-14
pubmed: 27373321
Front Immunol. 2017 Mar 22;8:318
pubmed: 28382039